Stockreport

New treatment for rare cancer cholangiocarcinoma approved in Australia

Incyte Corporation  (INCY) 
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
PDF Available to treat adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement PEMAZYRE® (pemigatinib) is available via a co-pay [Read more]